Clinical Trials Directory

Trials / Completed

CompletedNCT03402997

Tissue Resistivity in Breast Cancer Patients

Minimally Invasive Procedure for the Discrimination of Tissue Resistivity in Breast Cancer Patients

Status
Completed
Phase
Study type
Observational
Enrollment
105 (actual)
Sponsor
Ente Ospedaliero Cantonale, Bellinzona · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers

Summary

The resistivity measurements will be done by introducing a needle-probe into fresh healthy, peritumoral, and tumoral ex vivo tissues.

Detailed description

Patients affected by breast cancer will have their tissue analysed immediately following their surgical excision for the treatment of breast cancer. Two probes will be used: a linear probe of 4 needle-electrodes positioned in a row that is able to perform Electrical Impedance Spectroscopy (EIS) measurements and a circular probe of 8 needle-electrodes arranged into a circular pattern that is able to generate cross sectional images (Electrical Impedance Tomography maps). Firstly, the linear probe will be inserted in the tumor parenchyma at a penetration depth of about 2 mm and the tissue impedance measurement will be performed along a broad spectrum of frequencies for few minutes. Approximately 10 seconds for each measurement will be needed. Subsequently, if the size of the tissue will allow it, the circular probe will be inserted in the tumor parenchyma at the same penetration depth and 10 cross sectional maps will be generated (approximately 30 seconds in total). Both information obtained using the linear and the circular probes will be integrated for a full characterization of the tissue under examination.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTResistivity measurementTo measure and compare the tissue impedance values obtained by analysing ex vivo non-neoplastic (healthy and peritumoral) and neoplastic breast tissues

Timeline

Start date
2017-12-15
Primary completion
2019-09-25
Completion
2019-09-25
First posted
2018-01-18
Last updated
2019-12-12

Locations

1 site across 1 country: Switzerland

Source: ClinicalTrials.gov record NCT03402997. Inclusion in this directory is not an endorsement.